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The following extended abstracts were presented at a Research Initiatives 
in Vascular Disease Symposium, Vascular Gene Transfer: Models of Dis- 
ease and Therapy, sponsored by the National Heart, Lung, and Blood In- 
stitute of the National Institutes ofHealth, and the Lifeline Foundation fthe 
Society for Vascular Surgery and the North American Chapter, International 
Society for Cardiovascular Surgery on March 7-8, 1996, in Bethesda, Md. 
OVERVIEW ON GENE TRANSFER 
RECOMBINANT GENE TRANSFER:  
SC IENT IF IC  INS IGHTS,  D ISEASE 
PATHOGENESIS ,  AND ITS  POTENTIAL  TO 
TREAT HUMAN DISEASE 
During the past decade, significant progress has been made in 
understanding the genetic basis for congenital and acquired dis- 
eases. Concurrently, there have been substantial advances in 
lmowledge about he scientific basis for genentic development and 
its role in the disease process. This increased comprehension about 
the underlying mechanisms ha led to the evolution of gene 
transfer techniques to attempt correction of defective gene func- 
tion. There are several critical factors in the development of 
strategies for gene therapy. These include the type of vector used, 
the design of the vector, and the method of delivery. Many 
different approaches for employing ene transfer for the treatment 
of disease have been developed and evaluated. Until recently, viral 
vectors (e.g., retroviral, adenoviral and adeno-associated virus 
[AAV]) were the predominant method for delivering enes into 
cells because of their relatively high transduction efficiency. In 
response to growing concerns regarding the safety of viral vectors, 
considerable effort is now being expended to optimize nonviral 
delivery systems (naked DNA, DNA-liposome complexes, and 
particle-mediated delivery of DNA coated to inert beads). These 
endeavors have succeeded in providing a safer and viable alter- 
native for a number of applications. 1 
Ex vivo delivery has been the most commonly tested method 
for gene transfer in the past because it is often difficult o transduce 
target cells or tissue inside the patient; however, there are significant 
disadvantages to performing ene therapy in this manner. Ex vivo 
delivery necessitates that cells become stablished in cultures in the 
laboratory and survive the manipulations required for the trans- 
duction and subsequent selection of transformed cells before being 
reintroduced into the patient. Thus it subjects the cells to selection 
and different growth conditions from those that are exerted in vivo 
and requires that cell lines be established foreach malignancy. The 
adaptability of in vitro gene transfer approaches to human disease 
is therefore more difficult. There has recently been progress with in 
vivo gene transfer using nonviral vectors. Direct injection and 
catheter-based delivery of genes are two methods for effecting 
transduction of cells, although the scope of their utility is still 
limited. 
The development of appropriate vectors is another critical 
factor in providing effective gene therapy. In addition to containing 
the gene of interest, the vector must incorporate sequences that 
maximize the transcription and translation of the gene. Vector 
design and testing systems hav e improved considerably in recent 
years. Among the recent advances are the incorporation ofmultip!e 
genes into vectors and the development of vectors that can 
potentially cause the destruction of the transduced cells when 
specific drugs are administered, ensuring that gene xpression is
self-limiting. 
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Gene therapy techniques have been tested for the treatment of 
a number of inherited genetic disorders in which there are 
mutations in the coding or regulatory sequences. Attempts have 
been made to incorporate the adenosine deaminase (ADA) gene 
into human T lymphocytes to complement ADA deficiency, which 
leads to immune deficiency. Another study has used the LDL 
receptor gene in an effort to treat patients who are deficient in this 
receptor, resulting  hypercholesteremia. Studies are ongoing to 
develop gene therapies for cystic fibrosis using adenoviral vectors, 
as well as hemophilia (factor IX and VIII), phenylketonuria 
(phenylalanine hydroxylase, thalassemia (~-globin) and siclde cell 
anemia (~-globin). 2 In general, although the genetic lesions in 
these diseases are well understood, progress toward treatment has 
been limited by the need to express the gene in the appropriate 
tissues and regulate itappropriately and at sufficient levels to impact 
on these diseases. 
Gene therapy is now being developed for the treatment of a 
variety of diseases in addition to those caused by genetic defects. 
These conditions include cancer, cardiovascular disease, and infec- 
tious diseases. Important advances have been made in the use of 
gene therapy for the treatment of cancer. One approach focuses on 
enhancing the immune response against umors by the introduc- 
tion of genes directly into tmnor cells in vivo. The immune system 
is designed to provide protection against foreign agents. When the 
host is unable to recognize an organism or substance as foreign, the 
system fails to provide adequate protection, and the safety of the 
host is compromised. One method that is currently being tested is 
to administer a DNA/l iposome complex encoding for a class I 
MHC antigen directly into the tumor in vivo by direct injection r 
catheter-mediated d livery. When this gene is expressed on the cell 
surface of HLA-B7 negative individuals, it stimulates an immune 
reaction. It has been demonstrated that when this occurs, the host 
begins to recognize previously undetected antigens expressed by 
the cancer cells? '4 
The potential use of gene therapy to alter the course of 
infection by H1V is advancing through the testing of several 
different approaches, s These include decoys, antisense oligonucle- 
otides, ribozymes, and intracelfular immunization. Decoys are a 
method of causing cells to overexpress binding sequences. 6 When 
sequences specific to HIV are chosen, it is possible to reduce 
replication of the virus. 7-9 Antisense oligonucleotides, which bind 
to functional sequences in the HIV genome, are another method 
for treating HIV through genetic modulation. Their administra- 
tion potentially leads to disruption in HIV replication, m A third 
gene therapy method is the use of ribozymes, which are a more 
reactive form ofoligonucleotides, based on RNA catalytic function. 
These agents bind to the sequence, then cleave the nucleic acids 
from the structure. In this way, the virus is inactivated. Another area 
that is being pursued for the treatment of HIV is the use of genes 
encoding for transdominant egative proteins to interfere with the 
activation and regulation of HIV. This objective can be accom- 
plished through the retroviral and nonvirai delivery of the gene into 
CD4+ cells from HIV infected individuals. This approach is 
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currently being tested using Rev M10, a mutant form of the 
transdominant form of Rev. 
Both cell-mediated and direct gene transfer have been used in 
the optimization of gene therapies for vascular diseases, n Ceil- 
mediated gene transfer isan ex vivo procedure in which the vector 
is introduced into endothelial orsmooth muscle cells that have been 
harvested from an artery or vein and are maintained in cell culture. 
These cells are then delivered through acatheter into prespecified 
areas of an artery, where they establish t emselves. Investigations of 
vector delivery using replication-defective adenoviral vectors and 
DNA llposome complexes have been undertaken. The transfection 
efficiency provided by adenoviruses is higher than that obtained 
through other methods, but it is not yet known whether this 
expression elicits the desired reaction without causing toxicities. 
Improved nonviral vectors uch as DNA liposome complexes may 
provide an alternative approach. Recently, an adenoviral vector 
expressing herpesvirus thymidine ldnase was introduced invivo into 
bailoonqnjured porcine arteries. These cells responded to treat- 
ment with the nucleoside analog, ganciclovir, decreasing intimal 
hyperplasia) 2 Additional studies are now being conducted to 
optimize the vectors and delivery system. Several other gene 
products that arget cell proliferation, angiogenesis, or contractility 
have also shown promise in different animal models. 
Much progress has been made in understanding the role of 
specific genes in the pathogenesis of human disease. Gene therapy 
is now being tested in clinical studies for diverse medical problems. 
There is significant potential for this area of research to impact on 
both the understanding and treatment of a variety of human 
diseases. 
Gary Nabel, MD, PhD 
Elizabeth G. Nabel, MD 
University of Michigan 
Ann Arbor, Mich. 
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ANIMAL MODELS OF  D ISEASE 
L IP ID  D ISORDERS AND ATHEROSCLEROSIS  
IN  GENET ICALLY  MODIF IED MICE  
It is now generally accepted that he lesions ofatherosderosis begin 
as a result of some form of insult to the lining endothelial and 
smooth muscle cells of the artery wall. This insult can relatively 
rapidly lead to the development of a specialized, chronic inflam- 
matory response, characterized bythe presence of peripheral blood 
monocytes and T lymphocytes. In individuals with hyperiipidemia, 
transport of lipoproteins by the endothelial cells from the plasma 
into the artery wall may result in modification of some of these 
lipoproteins and, in part, to their oxidation. These modified 
lipoproteins may,-in turn, injure the overlying endothelial cells, 
resulting in continuing adherence ofmonocytes and T lymphocytes 
and to the development of chemotactic factors within the artery 
wall that draw these leukocytes between lining endothelial cells into 
the subjacent intima. 
Studies in human beings, nonhuman primates, rabbits, swine, 
and, most recently, hyperlipidemic, transgeulc ApoE-deficient mice 
demonstrate that one of the earliest observable changes within the 
artery is the increased adherence ofmonocytes and T lymphocytes 
to the endothellmn. These cells adhere to the endotheiium in 
clusters that appear to be localized throughout the arterial tree. 
Many of these adherent leukocytes are attached to the endothelium 
at sites of flow alteration, such as branches and bifurcations, as well 
as at the flow dividers within various parts of the artery. Before the 
appearance ofthese adherent leukocytes, particulate matter can be 
seen in the region between the endothellum and its underlying 
basement membrane. This particulate matter has the appearance of 
membranous whorls, as well as of lipoprotein particles, and has 
been described as liposome-like material. Thus there is evidence 
from human surgical and autopsy material and from specimens of 
experimental animals that monocyte and T lymphocyte adherence 
is preceded by the deposition of lipoid material beneath the 
endothelial cells. This lipoid material may somehow induce the 
formation of specific cell-surface adhesive glycoproteins on the 
surface of the endothelium, which could then lead to binding and 
attachment ofmonocytes and T ceils. 
The chemotactic attraction of these leukocytes into the artery 
leads to their localization subjacent to the endothelium and to the 
conversion of ma W of the subendothelial monocytes into mac- 
rophages or scavenger cells. These macrophages can actively bind 
and internalize the modified (oxidized) lipoproteins that may be 
present within the intimal space, become lipid laden, and take on 
the appearance of foam cells. Foam cell formation may lead to 
activation of the macrophages and to expression of genes for a series 
ofcytokines and growth-regulatory molecules. Cytoldnes that may 
be expressed by the macrophages include interleukin-1 (IL-1) and 
tumor necrosis factor (TNF), whereas the T lymphocytes may 
cxpress the gene'for interferon (IFN). In addition to the formation 
ofcytoldnes, the macrophages have the capacity to express genes for 
platelet-derived growth factors A and B (PDGF-A and PDGF-B), 
insulin-like growth factor 1 (IGF-1), hepatin-binding EGF-like 
growth factor (HB-EGF), and transforming rowth factor [3 
(TGF[3), as well as numerous others. The expression of these genes 
usually leads to their translation and, ultimately, to the possible 
secretion of these growth factors. Smooth muscle cells in the 
subjacent media of the artery wall contain receptors for PDGF, 
